search
Back to results

Almond Dose Response Study.

Primary Purpose

Hyperlipidemia, Diet Therapy, Cardiovascular Disease

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Full dose almonds
Half dose almonds+half dose muffin
Full dose whole wheat muffin
Sponsored by
University of Toronto
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperlipidemia focused on measuring RCT, Almonds, Hyperlipidemia, Blood Lipids

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and post-menopausal women
  • LDL-C >4.1 mmol/L at recruitment, aged 40-70, living within a 40 km radius of St. Michael's Hospital.

Exclusion Criteria:

  • Lipid lowering medications, clinical or biochemical evidence of diabetes, renal or hepatic disease, body mass index (BMI) >32 kg/m2, antibiotic use within the last three months, hormone replacement therapy, smoking or significant alcohol intake (> 1 drink/d) or triglyceride level >4.0 mmol/L.

Sites / Locations

  • St. Michael's Hospital

Outcomes

Primary Outcome Measures

Lipids: Total Cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoproteins B and AI
Glycemic control: Glucose, insulin, C-peptide (blood and urine).

Secondary Outcome Measures

Clotting Factors: fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor, urokinase, factor VII and factor VIII.
Oxidative Stress: Oxidized LDL-C as conjugated dienes in isolated LDL-C fraction, serum carotenoids, vitamin E, vitamin A; 8-hydroxy-2-deoxyguanosine (8-HDG) in isolated blood lymphocytes; malondialdehyde (MDA); urinary isoprostanes.
Nitric Oxide: Pulmonary (expired air) NO measured as a marker of whole body NO production and olfactory epithelial NO production in perfused nasal air.

Full Information

First Posted
July 24, 2007
Last Updated
July 25, 2007
Sponsor
University of Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT00507520
Brief Title
Almond Dose Response Study.
Official Title
The Effect of Almonds on Coronary Heart Disease Risk Factors: Dose Response Study.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2007
Overall Recruitment Status
Completed
Study Start Date
December 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2001 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Toronto

4. Oversight

5. Study Description

Brief Summary
To assess the effects of almonds on coronary heart disease (CHD) risk factors (serum lipids, measurements of oxidative stress and nitric oxide production) when added to the diets of subjects with high cholesterol. Also, to assess whether the amount of almonds consumed (i.e. almond dose) decreases CHD risk factors in a dose dependent manner. We hypothesize that since almonds have been shown to reduce serum lipids, we believe they will also increase nitric oxide levels related to their high levels of arginine and reduce markers of oxidative stress related to their content of bioactive phenolics. We anticipate that a dose-dependent relationship will be observed resulting in greater reductions in risk factors for coronary heart disease when greater doses of almonds are consumed.
Detailed Description
Previous studies have shown that nuts, specifically almonds, result in an improved coronary heart disease (CHD) lipid risk profile. Part of the reason has been ascribed to their high content of monounsaturated fat. However in a previous study we have done, the almond supplement, in comparison with an olive oil and dairy protein based supplement, still showed a significant reduction in total cholesterol (total-C) and low density lipoprotein cholesterol (LDL-C). We wish to use this paradigm to confirm the lipid lowering effect of almonds, to establish a similar relationship for the apolipoproteins and so add further support for the cardiovascular risk reduction associated with an almond diet. In addition, in view of the relatively high arginine content of almonds, we believe higher levels of nitric oxide (NO) will be produced, as indicated by increased NO in expired air from perfused olfactory mucosa. With this technique, we have found higher levels of NO in preliminary studies of subjects on soy diets. These data would further add to interest in nuts in relation to cardiovascular disease risk reduction. Furthermore, phenolics are present in high concentrations in oil seeds and nuts, and are known to have antioxidant activity. As yet, they do not appear to have been emphasized in relation to almonds. We will therefore determine the effect of feeding almonds on measures of oxidative stress, including oxidized LDL-C, considered to be of direct relevance to CHD; and oxidized DNA, of potential importance to neoplastic transformation and carcinogenesis. These studies could lead to assessment of postprandial effects of almonds to determine a mechanism, and to studies of cardiovascular effects of almonds including exercise stress tests and measures of vascular reactivity (e.g. forearm blood flow) in conjunction with NO measurements. Protocol: All subjects underwent three 4-week treatments in a randomized crossover trial. Background Diet: Subjects were instructed to follow the National Cholesterol Education Program (NCEP) Step 2 dietary guidelines. Nuts, soy and dietary supplements (vitamins, minerals or herbal remedies) were excluded in the background diet during all phases of the study. Treatments: The three phases were all weight maintaining, self-selected diets: control, full almond and half almond. Almond: Raw almonds were added as supplements to the subject's usual diet. Subjects with calorie needs of 2,400 kcal or greater, assessed by LRC tables, received the full almond supplement (100 g/d, approximately 600 kcal). Subjects requiring between 1,600-2,400 kcal daily received 75% of the full supplement (75 g/d, approximately 450 kcal). Subjects requiring less than 1,600 kcal daily received 50% of the full supplement (50 g/d, approximately 300 kcal). Control: The full control supplement was four 150 kcal muffins. Control supplements was matched with the energy content of the nut supplements; i.e. either 600 kcal/d (4 muffins); 450 kcal/d (3 muffins) or 300 kcal/d (2 muffins). The macronutrient composition of the muffins conformed to an NCEP Step 2 diet with 25% total fat, <7% saturated fat (by use of corn oil as the oil commonly used in healthy baked goods), with 18% protein (the average for our subject population using added skim milk powder), and zero cholesterol. Muffins were made with wheat flour. Half Portion: The Half Portion was matched with the energy content of the other two treatment periods. However on this treatment, half of the energy was derived from almonds and half from the control muffins. Design: Randomized crossover design. Duration: The study consisted of three months subject recruitment and selection; three 4-week treatment periods where supplements are provided, and at least two-week washout periods between supplements. (Total duration: approximately 7.5 months per subject). Study Details: Subjects came after a 12h overnight fast to the Risk Factor Modification Center at St. Michael's Hospital (Toronto) immediately prior to commencement of each study and at weekly intervals during the course of each study period. Prior to the start of the study, subjects were instructed on details of the study diet protocol. They were also asked to maintain a constant level of physical activity throughout the course of the study. At all visits, body weight (in kg) was obtained in indoor clothing, without shoes. Measurements: Bloods were taken at baseline and at weeks 2 and 4 of each phase. Pulmonary air was collected at baseline and at week 4 of each phase. Diet histories were recorded during the last week of each phase. Compliance:Compliance was assessed from completed one-week diet records where supplement intake is recorded. Diet records were reviewed by the dietitian with the subject at the end of the week. In addition, uneaten supplements were returned, weighed and noted on the menu plans by the dietitian.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperlipidemia, Diet Therapy, Cardiovascular Disease
Keywords
RCT, Almonds, Hyperlipidemia, Blood Lipids

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
Single
Allocation
Randomized
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Full dose almonds
Intervention Type
Procedure
Intervention Name(s)
Half dose almonds+half dose muffin
Intervention Type
Procedure
Intervention Name(s)
Full dose whole wheat muffin
Primary Outcome Measure Information:
Title
Lipids: Total Cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoproteins B and AI
Title
Glycemic control: Glucose, insulin, C-peptide (blood and urine).
Secondary Outcome Measure Information:
Title
Clotting Factors: fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor, urokinase, factor VII and factor VIII.
Title
Oxidative Stress: Oxidized LDL-C as conjugated dienes in isolated LDL-C fraction, serum carotenoids, vitamin E, vitamin A; 8-hydroxy-2-deoxyguanosine (8-HDG) in isolated blood lymphocytes; malondialdehyde (MDA); urinary isoprostanes.
Title
Nitric Oxide: Pulmonary (expired air) NO measured as a marker of whole body NO production and olfactory epithelial NO production in perfused nasal air.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and post-menopausal women LDL-C >4.1 mmol/L at recruitment, aged 40-70, living within a 40 km radius of St. Michael's Hospital. Exclusion Criteria: Lipid lowering medications, clinical or biochemical evidence of diabetes, renal or hepatic disease, body mass index (BMI) >32 kg/m2, antibiotic use within the last three months, hormone replacement therapy, smoking or significant alcohol intake (> 1 drink/d) or triglyceride level >4.0 mmol/L.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David JA Jenkins, MD, PhD
Organizational Affiliation
University of Toronto, St. Michael's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Cyril WC Kendall, PhD
Organizational Affiliation
University of Toronto, St. Michael's Hospital
Official's Role
Study Director
Facility Information:
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5S 2T2
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
12221048
Citation
Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, Haight JS, Faulkner D, Vidgen E, Lapsley KG, Spiller GA. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation. 2002 Sep 10;106(11):1327-32. doi: 10.1161/01.cir.0000028421.91733.20.
Results Reference
result
PubMed Identifier
33853731
Citation
Nishi SK, Kendall CWC, Bazinet RP, Hanley AJ, Comelli EM, Jenkins DJA, Sievenpiper JL. Almond Bioaccessibility in a Randomized Crossover Trial: Is a Calorie a Calorie? Mayo Clin Proc. 2021 Sep;96(9):2386-2397. doi: 10.1016/j.mayocp.2021.01.026. Epub 2021 Apr 11.
Results Reference
derived

Learn more about this trial

Almond Dose Response Study.

We'll reach out to this number within 24 hrs